Last €62.47 EUR
Change Today +0.134 / 0.21%
Volume 3.8K
As of 1:24 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (ZEG) Snapshot

Open
€60.99
Previous Close
€62.34
Day High
€62.47
Day Low
€60.99
52 Week High
01/28/15 - €64.28
52 Week Low
04/14/14 - €44.66
Market Cap
78.9B
Average Volume 10 Days
9.7K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
--
Dividend
€2.92
Dividend Yield
4.19%
Current Stock Chart for ASTRAZENECA PLC (ZEG)

astrazeneca plc (ZEG) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

Founded in 1992

astrazeneca plc (ZEG) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (ZEG) Key Developments

AstraZeneca PLC Proposes Board Changes

AstraZeneca announced that Dr. Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company's Annual General Meeting (AGM) on 24 April 2015. On election, the Board also proposes appointing Dr. Bargmann to AstraZeneca's Science Committee. John Varley, senior independent Non-Executive Director and Dame Nancy Rothwell, Non-Executive Director, both intend to retire from the Board at the close of the AGM on 24 April 2015, each having served as a Board member for nine years. John is currently Chairman of the Remuneration Committee and a member of the Nomination and Governance Committee. Dame Nancy Rothwell is currently Chairman of the Science Committee, and a member of the Remuneration Committee and the Nomination and Governance Committee. As a result of the retirement of John Varley and Dame Nancy Rothwell, the following Board Committee changes will take place with effect from the close of the AstraZeneca 2015 AGM: Rudy Markham will become senior independent Non-Executive Director. Graham Chipchase will become Chairman of the Remuneration Committee and a member of the Nomination and Governance Committee. Bruce Burlington will become Chairman of the Science Committee and a member of the Nomination and Governance Committee. Geneviève Berger will oversee sustainability matters on behalf of the Board. In addition, Shriti Vadera will become a member of the Remuneration Committee with immediate effect.

AstraZeneca Provides Earnings Guidance for the Year 2015

AstraZeneca provided earnings guidance for the year 2015. For the year, the company announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834, protecting PULMICORT RESPULES in the US, is invalid. This decision will not impact the company guidance for 2015, which is that sales revenue is expected to decline by mid single-digit percentage at constant exchange rates (CER) and core EPS is expected to increase by low single-digit percentage at CER.

AstraZeneca To Sell Its Anti-Infectives Division

AstraZeneca PLC (LSE:AZN) seeking an investor for its anti-infectives division, FierceBiotech has learned. AstraZeneca is now coming to a final decision. "AstraZeneca had a formal process underway where they were pitching spinning off the business and AstraZeneca being the lead shareholder," one executive close to the bargaining table tells me. Another player in the field said, "The challenge was that they wanted to spin out the whole pipeline plus a 20-person team. The pipeline had a couple of interesting assets but they wanted to get paid for the uninteresting assets as well."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €62.47 EUR +0.134

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.52 USD -0.10
Actavis plc $289.78 USD -0.62
Biogen Idec Inc $410.10 USD +1.16
Celgene Corp $123.35 USD +0.25
Eli Lilly & Co $70.03 USD -0.33
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 71.7x
Price/Sales 3.4x
Price/Book 4.5x
Price/Cash Flow 71.6x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.